EUVIMEDEUVIMED entdecken
Crossref

Neutrophil‐To‐Lymphocyte Ratio and Survival in Pembrolizumab‐Treated Oropharyngeal Cancer

Angeline A Truong iD, Savinnie Ho, Rex H Lee iD, Xin Wu, Hyunseok Kang iD, Ivan H El-Sayed iD, Jonathan R George, Chase M Heaton iD, Ilya Likhterov, Mary Jue Xu, Patrick K Ha iD, Alain P Algazi und 1 weitere

Head & Neck · 2026

DOI: 10.1002/hed.70312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Angeline A Truong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Oropharyngeal Neoplasms, Neutrophils, Antineoplastic Agents, Immunological. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A minority of patients receiving immunotherapy for oropharyngeal head and neck squamous cell carcinoma benefit. Finding biomarkers that predict response to ICI is important for improving outcomes in these patients. In this study, we determine the relationship between pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and 6‐month progression‐free survival (PFS)/2‐year overall survival (OS) among patients with recurrent or metastatic (R/M) oropharyngeal cancer on pembrolizumab.

Methods

This study was a retrospective cohort study of patients with recurrent/metastatic OPSCC who were treated with pembrolizumab between May 2016 and May 2022 at a tertiary care academic center. The primary outcome was 6‐month progression‐free survival. The secondary outcome was 2‐year overall survival. NLR was treated as a continuous and dichotomous variable. Disease progression was determined using radiographic criteria adopted from the Response Evaluation Criteria in Solid Tumors.

Results

Sixty‐four patients with OPSCC were included. The median pre‐treatment NLR was 5.1 (IQR 3.1–8.3). Thirty‐seven (58%) patients had distant metastases at the start of ICI. When treated as a continuous variable, higher pretreatment NLR was associated with poorer 6‐month PFS [HR 1.14 (1.03, 1.27), p = 0.016] and 2‐year OS [HR 1.21 (1.09, 1.35), p = 0.001] for patients on pembrolizumab. Subgroup analyzes on patients who were p16+ versus p16‐ revealed that NLR was only associated with poorer survival for p16+ patients [HR 1.16 (1.00, 1.33), p = 0.046 versus HR 1.11 (0.94, 1.31), p = 0.203, respectively].

Conclusion

Higher pretreatment NLR was associated with poorer 6‐month PFS and 2‐year OS in OPSCC patients treated with pembrolizumab. When stratified by p16 status, this association only remained significant among p16+ patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedOropharyngeal NeoplasmsNeutrophilsAntineoplastic Agents, ImmunologicalLymphocytesSquamous Cell Carcinoma of Head and NeckHumansFemaleMaleRetrospective StudiesMiddle AgedAgedProgression-Free SurvivalNeoplasm Recurrence, LocalCohort Studies

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
  • Department of Medicine, University of California, San Francisco, California, USA.

ORCID-Profile: Angeline A Truong, Rex H Lee, Hyunseok Kang, Ivan H El-Sayed, Chase M Heaton, Patrick K Ha, Katherine C Wai

Zitieren

APA

Truong, A. A., Ho, S., Lee, R. H., Wu, X., Kang, H., El-Sayed, I. H., George, J. R., Heaton, C. M., Likhterov, I., Xu, M. J., Ha, P. K., Algazi, A. P., & Wai, K. C. (2026). Neutrophil‐To‐Lymphocyte Ratio and Survival in Pembrolizumab‐Treated Oropharyngeal Cancer. Head & Neck. https://doi.org/10.1002/hed.70312

Vancouver

Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, et al. Neutrophil‐To‐Lymphocyte Ratio and Survival in Pembrolizumab‐Treated Oropharyngeal Cancer. Head & Neck. 2026. doi:10.1002/hed.70312

BibTeX
@article{Truong2026,
  author = {Truong, Angeline A and Ho, Savinnie and Lee, Rex H and Wu, Xin and Kang, Hyunseok and El-Sayed, Ivan H and George, Jonathan R and Heaton, Chase M and Likhterov, Ilya and Xu, Mary Jue and Ha, Patrick K and Algazi, Alain P and Wai, Katherine C},
  title = {Neutrophil‐To‐Lymphocyte Ratio and Survival in Pembrolizumab‐Treated Oropharyngeal Cancer},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70312}
}
Kostenlos starten →